PVR and neoplasm: Interactions between CD155 and CD112 on tumor cells and DNAM-1 on NK and T cells augment cell-mediated cytotoxicity and cytokine production [7, 8]; DNAM-1 is likely involved in immunity against CD155- and CD112-expressing malignant tumors.